{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:20:59Z","timestamp":1793942459096,"version":"4.8.0"},"reference-count":4,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.1001\/jamaoncol.2022.4346","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:36:36Z","timestamp":1663846596000},"page":"1700","source":"Crossref","is-referenced-by-count":2,"title":["Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases\u2014Reply"],"prefix":"10.1001","volume":"8","author":[{"given":"Debu","family":"Tripathy","sequence":"first","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Nektar Therapeutics, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"clr220017r1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamaoncol.2022.0514","article-title":"Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial.","volume":"8","author":"Tripathy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"20","key":"clr220017r2","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1200\/JCO.2014.58.8517","article-title":"Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases.","volume":"33","author":"Subbiah","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"clr220017r3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/S1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician\u2019s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"clr220017r4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ygyno.2017.08.026","article-title":"A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.","volume":"147","author":"Rustin","year":"2017","journal-title":"Gynecol Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2796768\/jamaoncology_tripathy_2022_lr_220017_1668658017.05018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:04:00Z","timestamp":1668683040000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2796768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.4346","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}